Back to search

Agricultural University of Athens

Μελέτη του ρόλου της κυτταροκίνης RANKL σε οστεοανοσολογικές αλληλεπιδράσεις με διαγονιδιακά ζωικά μοντέλα οστικής απώλειας

Abstract

dc:description

Receptor Αctivator of Νuclear factor Κappa-B Ligand (RANKL), a member of the Tumor Necrosis Factor (TNF) superfamily, constitutes the master regulator of osteoclast formation and bone resorption. RANKL binds and activates its receptor, RANK, and consequently induces the differentiation, maturation and survival of osteoclasts, which are the main cells responsible for bone resorption. In humans, functional mutations in the RANKL gene cause Autosomal Recessive Osteopetrosis (ARO), whereas overproduction of RANKL is accociated with a plethora of bone degenerative pathologies, such as osteoporosis and rheumatoid arthritis. Targeted inhibition of RANKL by administration of a monoclonal antibody (Denosumab, Dmab) effectively reduces the increased rate of fractures observed in menopausal women, constituting the new treatment for osteoporosis. Moreover, it is known that RANKL significantly affects the maturation and activation of the immune system since knockout mice that cannot produce RANKL, display severe osteopetrosis due to the absence of osteoclasts, but also thymic hypoplasia, absence of lymph nodes and a decrease in B lymphocytes. However, it remains unclear whether adundant RANKL affects leukocyte populations in lymphoid organs, as well as inflammatory bone diseases, such as rheumatoid arthritis. Dr Eleni’s Douni research group has generated in the past, two transgenic models of osteoporosis that overproduce the human RANKL (huRANKL) protein (TgRANKL) through genetic engineering. Tg5516 transgenic mice expressing low levels of huRANKL develop mild osteoporosis, whereas, Tg5519 transgenic mice overexpress huRANKL and display severe osteoporosis. Moreover, the same group has also generated RANKLtles/tles mice, which display severe osteopetrosis, due to a functional mutation in the Rankl gene. These animal models, consist excellent tools to investigate the role of RANKL in the immune system and in inflammatory diseases. In the present PhD thesis, we investigated a) whether overexpression of RANKL in osteoporotic TgRANKL mice affects leukocyte maturation in primary and secondary lymphoid organs in order to understand the osteoimmunological interactions that take place under osteoporotic conditions, b) the role of RANKL in inflammatory arthritis by inactivating or overexpressing RANKL in the TNF-mediated Tg197 transgenic mouse model of arthritis, and c) the protein profile of Tg197/TgRANKL double transgenic mice that overexpress TNF and RANKL compared with the protein profile of the Tg197 arthritic and Tg5519 osteoporotic littermates, in order to study the pathogenetic mechanisms induced by overexpression of RANKL in inflammatory diseases.Analysis of lymphoid organs with flow cytometry showed significant differences between Tg5519 and WT mice. Specifically, bone marrow (BM) analysis of Tg5519 mice revealed a progressive reduction of leukocyte numbers at the age of 6 months, due to the increased adipogenesis that takes place in BM impairing hematopoiesis. Moreover, a selective increase in the percentage of B lymphocytes was also identified, indicating an acceleration in B lymphocyte maturation process. In thymus, although there were no differences in the total number of thymocytes, the immature double positive CD4+CD8+ cell population was significantly reduced while mature CD4+ and CD8+ populations increased, indicating an accelerated T cell differentiation process in Tg5519 mice. Analysis of spleen showed a significant decrease in leukocytes at 8 months of age, as a result of reduced BM hematopoiesis. However, at younger ages Tg5519 mice showed a significant increase in the B lymphocyte population, which is consistent with the analysis of BM. Peripheral blood also showed a significant decrease in leukocytes at 8 months. A similar analysis at 6 months of age in Tg5516 transgenic mice showed no significant differences in leukocytes of lymphoid organs compared to WT mice, probably reflecting the restricted bone marrow adiposity in the Tg5516 line.At the second part of our results, we used the human TNF transgenic mouse model of erosive inammatory arthritis, Tg197, to determine if the progression of inammation is affected by either genetic inactivation or overexpression of RANKL in transgenic mouse models. TNF-mediated inammatory arthritis was signicantly attenuated in the absence of functional RANKL. Our results also demonstated that RANKL is necessary for physiological bone remodeling and inflammation-induced bone destruction. Notably, TNF overexpression could not compensate for RANKL-mediated osteopetrosis, but promoted limited osteoclastogenesis between the pannus and bone interface, suggesting RANKL-independent mechanisms of osteoclastogenesis in inamed joints. On the other hand, simultaneous overexpression of RANKL and TNF in double transgenic mice accelerated disease onset and led to severe arthritis characterized by signicantly elevated clinical and histological scores as shown by aggressive pannus formation, extended bone resorption, and massive accumulation of inammatory cells, mainly of myeloid origin. RANKL and TNF cooperated not only in local bone loss identied in the inamed calcaneous bone, but also systemically in distal femurs as shown by microCT analysis. Proteomic analysis in inamed ankles from double transgenic mice overexpressing human TNF and RANKL showed an abundance of proteins involved in osteoclastogenesis, pro-inammatory processes, gene expression regulation, and cell proliferation compared to Tg197 and Tg5519 single transgenic mice. Collectively, these results suggest that RANKL modulates modeled inammatory arthritis not only as a mediator of osteoclastogenesis and bone resorption but also as a disease modier affecting inammation and immune activation. In conclusion, our study suggests that a dual inhibition of RANKL and TNF could be a more effective treatment in RA than existing ones, as it would simultaneously target both inflammation and bone destruction.

Degree

thesis:*
Grantor dc:publisher
Agricultural University of Athens
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadaki, Maria
  • Παπαδάκη, Μαρία

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/46557

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadaki, Maria; Παπαδάκη, Μαρία. Μελέτη του ρόλου της κυτταροκίνης RANKL σε οστεοανοσολογικές αλληλεπιδράσεις με διαγονιδιακά ζωικά μοντέλα οστικής απώλειας. Agricultural University of Athens, 2019. http://hdl.handle.net/10442/hedi/46557